The immuno-oncology antibody developer added $7m to a round already containing University of Texas system's MD Anderson, which helped spin out OncoResponse a year ago.
OncoResponse, a US-based company researching antibodies for immune-oncology treatments, added $7m yesterday to a corporate-backed series A round that now totals $19.5m.
Helsinn Investment Fund, the unit recently launched by cancer care provider Helsinn, and venture capital firm GreatPoint Ventures each provided $3.5m. Baxalta, the biopharmaceutical company since acquired by pharmaceutical firm Shire, had invested $3m in June 2016.
MD Anderson, a research institute of University of Texas system, Arch Venture Partners, the VC firm spun out of…
